Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that company management will participate in three upcoming investor conferences taking place in New York City in February.
  • Canaccord Genuity Rare Disease and BioPharma One-on-One Day – February 7, 2017
  • BIO CEO & Investor Conference – February 13, 2017; presentation at 10:30am EST
  • SunTrust Robinson Humphrey Orphan Drug Day – February 14, 2017

For the Canaccord Genuity and SunTrust Robinson Humphrey events, the Company will participate in one on one meetings. A live audio webcast of the BIO CEO & Investor Conference presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics Glyn Edwards / Richard Pye (UK office)Erik Ostrowski / Michelle Avery (US office)    Tel: +44 (0)1235 443 951        +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser)Liam Murray / Tony Rawlinson   Tel: +44 (0)20 7213 0880
N+1 Singer (Broker)Aubrey Powell / Jen Boorer     Tel: +44 (0)20 7496 3000
MacDougall Biomedical Communications(US media contact)Chris Erdman / Karen Sharma   Tel: +1 781 235 3060 cerdman@macbiocom.comksharma@macbiocom.com
Consilium Strategic Communications (Financial public relations, UK)Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville Tel: +44 (0)20 3709 5700summit@consilium-comms.com

-END-

Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Summit Therapeutics Charts.
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Summit Therapeutics Charts.